

**PCR Detection of Mixed and Zoonoses Malaria using *Plasmodium spp* Dynein Light Chain  
(dlc-tctex) Gene.**

**“Abstract”**

Novel gene targets are needed in accurate diagnosis of malaria. Previous studies show that the dynein light chains (*dlc*) in *Plasmodium* are uniquely conserved within the species, possibly due to their role as the cargo adaptor moiety. This study aimed at development of PCR assay for detection of *Plasmodium* based on the (*dlc-Tctex*) as a genus and species-specific tool in malaria diagnosis. Multiple primers were designed based on *Plasmodium spp dlc(Tctex)* genes. The primers were applied on PCR to detect malaria on clinical samples and on laboratory maintained isolates of *P. falciparum* and *P. vivax* for human infecting species and *P.knowlesi* and *P.cynomolgi* for zoonoses infection involving primates. The amplified PCR fragments were gene cleaned and sequenced. BLASTn e-values output from the raw nucleotide queries support that the genes are uniquely conserved. Species-specific primers amplified *P. falciparum* infections with no cross-reactivity to *P. vivax*, *P. knowlesi* or *P. cynomolgi* species. In this assay only 11 out of the 30 microscope positive malaria positive clinical blood samples were positive for PCR detection of *P. falciparum* infection. Primers designed for *Plasmodium* genus amplified the target band in all clinical malaria samples but also had another band amplification that was specific. This is preliminary data demonstrate that a species-specific *dlc(Tctex)* PCR assay can be used for detection of *P. falciparum* and optimized genus primers can be applied to differentiate mixed malaria infections.

*Keyword: Plasmodium malaria, PCR detection, dlc-Tctex.*

## 1.0. Introduction:

Malaria infection is a major public health problem in tropical and subtropical regions of the world. Pregnant women and children below five years of age are at a higher risk of malaria than adults due to their relatively low immunity [1-5]. The disease is caused by infection of red blood cells by protozoan parasites of the genus *Plasmodium* that are inoculated into the human host by female anopheline mosquito while feeding [5, 6]. The four *Plasmodium* species that infect humans are *P. falciparum*, *P. vivax*, *P. malariae*, and *P. ovale*. *P. falciparum* and *P. vivax* are the most widespread and common causes of mixed-species malaria [7]. Increasingly, human infections with the non-human primate malaria parasites *P. cynomolgi* and *P. knowlesi* are being reported in South East Asia [8-12]. *P. knowlesi* has a 24-hour asexual life cycle, the shortest observed thus far, for human-infecting parasites. This short cycle can lead to rapid increases in parasitaemia hence severe disease including fatalities as reported in recent studies [11]. Microscopically, *P. knowlesi* exhibits stage-dependent morphological similarities to *P. malariae* and these similarities have contributed to misdiagnosis of *P. knowlesi* as *P. malariae*, a relatively benign disease [11, 13].

The first symptoms of malaria are non-specific and similar to the symptoms of a minor systemic viral infection: headache, lassitude, fatigue, abdominal discomfort, muscle and joint aches, usually followed by fever, chills, perspiration, anorexia, vomiting and worsening malaise [13-17]. Malaria is thus frequently over-diagnosed on the basis of symptoms alone, especially in endemic areas. Conversely, in missed diagnosis malaria cases, delayed treatment or wrong prescription of medicines for for *P. falciparum* cases, the parasite burden rises in the less-immune individuals and severe malaria may occur within a few hours. At this stage, fatality in

people receiving treatment is typically 10% to 20% and if further delayed, severe malaria is fatal in the majority of cases [18, 19].

Recommended methods for routine diagnosis of malaria are observation of parasite in peripheral blood parasite by microscopy and detection of parasite antigens by rapid diagnostic tests (RDTs) [20]. There has been observed limitations in these methods in differentiating mixed-species malaria infections. This has impact on therapeutic decisions, including selection, dose, and timing of anti-malarial drugs. Treatment for a single species, rather than multiple species, can have serious clinical consequences and the current reports of zoonoses infections is a concern [8, 11]. In addition, mixed-species infections are related to the growing problem of anti-malarial drug resistance, which can enable emergence of drug-resistant clones of *Plasmodium* parasites and relapse infection [20-22]. In recent years, several polymerase chain reaction assays have been developed and evaluated for malaria diagnosing, most often based on species-specific sequences of the parasites' 18S small subunit rRNA gene[23-25]. In our previous *in silico* study done on the *Plasmodium* spp. dynein light chain genes, the *dlc-TcTex1* genes were found to be conserved within the *species* and had low similarity to human orthologues [26]. These differences can be attributed to variations in the cargo attached via the *dlc* adaptors to the main dynein motor complex [27]. In this study we analyze application of *dlc-Tctex* gene in PCR detection of *Plasmodium spp* as an additional tool for differentiating mixed malaria and zoonoses infections.

## **2.0. Materials and Methods:**

### **2.1.1 Laboratory derived Samples:**

Extracted DNA sample of laboratory culture isolates or laboratory animal propagated plasmodial parasites were kindly provided: *P. falciparum* (David Peterson, University of Georgia, USA), *P. Knowlesi* (Julian Rayner, Sanger Institute, UK), *P. vivax* (Robert Moon, London School of Hygiene and Tropical Medicine (LSHTM), UK), *P. cynomolgi* (Jenneby Mamun, Institute of Primate Research, Kenya (IPR)).

### **2.1.2 Clinical samples:**

Ethical clearance for sampling blood from human subjects was obtained from Kenyatta National Hospital/University of Nairobi Ethics Committee (KNH/UON). Sampling was done in coast region of Kenya endemic to malaria. This study involved patients who went freely for clinical check up at Coast General hospital and Sacred Medical clinic, Mombasa. In presumptive malaria cases, approximately 500ul (microliter) of blood was collected in EDTA vacutainer (Benton and Dickson), an aliquot for microscopy observation separated, and the rest of the blood was stored in the laboratory at -20°C. Laboratory tests by microscopy was carried out where 42 samples were classified malaria positive but only 30 of these samples were non-ambiguous.

### **2.1.3 Ethics statement:**

This research project was conducted with approval of both Institute of Primate Research/National Museums of Kenya scientific committee and Pan African University of Basic Sciences-Jomo Kenyatta University of Agriculture and Technology graduate students project approval committee. Due to the use of human subjects, clearance was sought from KNH/UON

Ethics committee (above) in accordance to the Helsinki Declaration of 1975, as revised in 2000. Patients coming to the clinic were informed about the study through posters and personal contact and the study objectives were explained in English or in Kiswahili (vernacular). Patients expressing interest to participate got more information on potential risks. Questionnaire form cleared by KNH/UON ethics committee was applied to check subjects' understanding that the study intent is to improve on malaria diagnosis.. For individuals under 18 years, parents gave the consent to participate by signing on behalf.

## **2.2 DNA Extraction:**

200ul of blood was aliquoted into 1.5ml microcentrifuge tubes for DNA extraction. Briefly, 20ul ProteinaseK was added to sample and 200ul of digestion/lysis buffer and incubated at 56°C in a water-bath. DNA was bound to silica matrix spin column, washed and eluted in 100ul-to-200ul nuclease free distilled de-ionized water, as described in owner's manual (Invitrogen, Grand Island, NY 14072, USA ) and stored at -20°C.

## **2.3 Primers and PCR:**

*P. falciparum* specific primers were designed based on *Plasmodium dlc* gene sequences obtained from NCBI nucleotide database [27, 28]. These were aligned by Clustal-W software in the BioEdit Suite (BioEdit v7.0.5 copyright (c) 1997–2005) against human and related *dlc* sequences (Supplementary data, Table 1). Similarly, *Plasmodium* genus and species specific primer sets were designed based on respective conserved sequences. PCR amplification was done using 100ng of the template DNA, 0.5uM of each primer, 200uM each dNTP, 10X buffer with 2.0mM MgCl<sub>2</sub> and 0.5U Takara Taq polymerase (Takara Inc. Japan), made up to 25ul with

ddH<sub>2</sub>O. Cycling conditions: Taq polymerase activation 92°C, 3 min; 35cycles profile:- denaturation, 92°C, 1 min; annealing, 52°C-to- 57°C, 1 min; Taq polymerase nucleotide elongation, 70°C, 1 min; final polymerase extension step, 70°C, 3 min and final storage in the PCR machine at 8°C.

#### **2.4 Gene Clean and Sequencing:**

The different *Plasmodium* species control samples and clinical blood samples that were positive for malaria by PCR using *P. falciparum* specific and genus specific primers were re-amplified for purposes of sequencing. PCR products were analyzed on 1% agarose gel and the DNA viewed via ethidium-bromide fluorescence in ultra-violet transilluminator. The target fragments were excised from the gel and dissolved in sodium iodide solution at 56°C, then applied to the purification column (innuPREP gel extraction kit, Lifescience, Jena, Germany). DNA was eluted in 35ul nuclease-free ddH<sub>2</sub>O. Eluted fragments were sent (Macrogen Inc. Netherlands) for custom sequencing in 454 Sanger's di-deoxy sequencing procedures.

#### **2.5 Raw Sequence Editing and BLASTn Procedures:**

Raw sequences were Clustal-W aligned in BioEdit suite program and 20-to-30 nucleotides at the 5'end and 3'end trimmed. Consensus sequence derived from three repeat sequences was applied in BLASTn analysis. Representative sequences were used as queries against NCBI non-redundant nucleotide databases using BLASTn [28, 29] at default algorithm parameters (expectation thresh hold of 10) to identify orthologous and paralogous genes.

### 3.0. Results:

#### 3.1 *P. falciparum* specific PCR products:

*P. falciparum* specific primers PCR performed on different *Plasmodium* species control and clinical samples produced a band approximately 300bps. 3D7 *P. falciparum* laboratory culture controls and some of clinical samples positive for malaria had distinctive PCR product while others had faint or no bands. (Fig1a). Out of the 30 clinical blood samples which had been found to be positive of malaria through microscopy, only 11 had clear positive for *P. falciparum* by PCR. The samples re-amplified for sequencing purposes are shown (Fig 1b).




Fig 1a. PCR products (*P. falciparum* specific primers). Lane1; Mol wt marker; clinical malaria samples: lane 2; KS3, lane 3; KS4, lane 4; H9C, lane 5; K10, lane 6; Dd2; lane 7, PR26D; lane 8, 3D7; lane 9, Mumias1; lane 10, Mumias2; lane 11, G9; lane 12, B3; lane 13, B1; lane 14, PR26D; lane15, H9C.




Figure 1b. (Gene Clean products): Lane 1, Mol wt marker; lane 2, buffer only; lane 3 & 4 Malaria –ve human DNA samples, lane 5, 3D7 control; lane 6- 10 clinical malaria samples.

### 3.2 Genus specific PCR products:

PCR performed using genus specific primers produced variant size band in the respective species. *P. falciparum* (3D7 and Dd2), *P. vivax*, *P. cynomolgi* and *P. knowlesi* control samples produced a band approximate of 300bps (Fig 2 (A), (B), (C)) but *P. vivax*, *P. cynomolgi* and *P. knowlesi* produced another band approximately 450bps. Experimental primates derived *P. knowlesi* and *P. vivax* and some *P. falciparum* samples also produced approximately 700bps and 1000bps product. The extra PCR products in *P. knowlesi* and *P. falciparum* samples could be eliminated by application of stringent PCR conditions but remained persistent in all *P. vivax* positive samples (Fig 2 (c)).




Fig 2. (A). PCR (Genus primers). Lane 1; Mol wt marker, lane 2; *P.cynomolgi*, lane 3; *P.vivax*, lane 4; *P. falciparum* (3D7), lane 5; *P. falciparum* (Dd2)  
 (B). PCR (Genus primers). Lane 1; Mol wt marker, lane 2, Malaria (negative), lane 3; *P. falciparum* (Dd2); lane 4, *P.vivax*; lane 5; *P.kowlesi* (Sanger Institute), lane 6; *P. knowlesi* (IPR).  
 (C). PCR (Genus primers, stringent conditions PCR). Lane 1, Mol wt marker; lane 2, *P. falciparum* (3D7); lane 3; *P. falciparum* (Dd2); lane 4, *P.vivax*; lane 5; *P. knowlesi* (Sanger Institute), lane 6; *P.knowlesi* (IPR).

When these primers were applied in clinical human blood samples, they produced at least one band in the clinical samples that corresponded to the control samples (270bps – to- 300bps) product but also amplified another gene target approximately 1000bps band (Fig 3(A), (B), (C)). These target PCR products (Figure 4 (A), (B)) were gene cleaned for sequencing purposes (Fig 4 (C)).




Fig. 3 (A): Clinical samples PCR (Genus primers). Lane1, Mol wt maker; Lane2, Malaria -ve sample; Lane3, *P. vivax*; Lane4, *P. cynomolgi*; Lane 5- to- 16 (clinical samples)  
 (B): Clinical samples PCR (Genus primers). Lane 1, Mol wt marker; lane 2, *P. falciparum* (3D7); lane 3; *P. falciparum* (Dd2); lane 4, *P. vivax*; lane 5; *P. knowlesi* (Sanger Institute), lane 6; *P. knowlesi* (IPR); lane 7- to- 13 (clinical samples)  
 (C): Varied clinical samples PCR (Genus primers). Lane 1 and 14, Mol wt marker; lane 2, *P. falciparum* (3D7); lane 3, *P. vivax*; lane 4; *P. knowlesi* (Sanger Institute); lane 5- to- 13 and 15 to- 21 (clinical samples)




Fig. 4. (A): PCR (Genus primers). Lane1; Mol wt maker; lane 2. *P.falciparum*; lane 3, *P. vivax*; lane 4, *P. Knowlesi*; lane 5 –to– 13, clinical malaria samples.

(B) PCR (Genus primers). Lane1; *P.cynomolgi*; lane 2, *P. vivax*; lane 3, *P. falciparum* (3D7); lane 4, *P. falciparum* (Dd2); clinical malaria samples:- lane 5. KS4; lane 6, KS3; lane7, MP20.

(C). Gene Clean samples for sequencing. Lanes1-5, 1000bps band clinical samples viz G10A, KS3A, H9CA, B1A and B5A; lane 6, B5B (400bps); lane7, MP20A (1000Bps); lane8, MP20B (400Bps); lane 9, *P. knowlesi* (1000bp); lane10, *P. knowlesi* (400bps); lane11, *P.cynamolgi* (1000bp); lane12, *P.cynamolgi*(400bps); lane 13, *P. knowlesi*-new (400bp); lane 14, *P. knowlesi*-new (1000bp).

### 3.3 BLAST analysis of nucleotide sequences

The raw DNA sequences were initially edited at the 5' and 3' prime end. Respective consensus sequences BLAST against NCBI non redundant nucleotide database showed species specific results. Each of the species specific primers derived sequences produced high score respective to the species (Table 1). The representative sequences from this work are deposited at

NCBI nucleotide data base (GenBank accession id: KM263613.1 -to- KM263613.1). BLASTn results based on *P. falciparum* specific primers produced expectation value (e-value  $3e^{-151}$ ) for 3D7 dynein light chain type 2, while the nearest neighbor, *P. berghei*, had e-value  $4e^{-23}$  and there was no closely related human sequence observed (Table 1 (A)). BLASTn output obtained from nucleotide sequences derived from *Plasmodium* genus specific primers showed interchangeable results where the high score for *P. knowlesi* dynein light chain type 2 had e-value  $9e^{-158}$  and *P. cynomolgi* e-value  $4e^{-112}$  (Table1; (B) & (C)) while *P. vivax* had the highest near neighbor score, e-value  $1e^{-98}$  and no significant score against human derived nucleotide sequences. The genus primers targeted *P. knowlesi* sub-class and the BLASTn results showed this specificity. Similarly, BLASTn results from field clinical samples PCR fragment sequence query (6PB and 7PB) had high score hits (e-value  $1e^{-124}$ - $1e^{53}$ ) within *P. vivax* , *P. knowlesi* and *P. cynomolgi* reflecting this target subclass of *Plasmodium* species (Table 2).

**Tables:****Sequences producing significant alignments:****(A). *Plasmodium falciparum***

<b>Description</b>	<b>E value</b>	<b>Accession</b>
<i>P. falciparum</i> 3D7 chromosome 11, complete	3e <sup>-151</sup>	AE014186.2
<i>P. falciparum</i> 3D7 DLC type 2, complete cds	3e <sup>-151</sup>	XM_001347783.1
<i>P. berghei</i> strain ANKA DLC type 2, mRNA	4e <sup>-23</sup>	XM_673772.1
<i>P. inui</i> San Antonio 1 hypothetical protein mRNA	8e <sup>-19</sup>	XM_008819688.1
<i>P. knowlesi</i> strain H DLC type 2 complete cds	4e <sup>-16</sup>	XM_002259103.1
<i>P. knowlesi</i> strain H chromosome 9, complete genome	4e <sup>-16</sup>	AM910991.1
<i>P. cynomolgi</i> strain B DLC type 2 complete cds	2e <sup>-13</sup>	XM_004222316.1
<i>P. vivax</i> SaI-1 DLC type 2 partial mRNA	2e <sup>-13</sup>	XM_001615210.1
<i>D. globosa</i> 5.8S rRNA gene 28S rRNA	0.001	KJ136787.1
<i>H. sapiens</i> ankyrin repeat, chromosome 12	0.001	NG_029860.1
<i>H. sapiens</i> 12 BAC RP11-179A1 complete sequence	0.001	AC079954.18

**(B). *Plasmodium knowlesi***

<b>Description</b>	<b>E value</b>	<b>Accession</b>
<i>P. knowlesi</i> strain H DLC type 2 complete cds	9e <sup>-158</sup>	XM_002259103.1
<i>P. knowlesi</i> strain H chromosome 9, complete	9e <sup>-158</sup>	AM910991.1
<i>P. cynomolgi</i> strain B DLC type 2 complete cds	4e <sup>-112</sup>	XM_004222316.1
<i>P. vivax</i> SaI-1 DLC type 2 partial mRNA	1e <sup>-98</sup>	XM_001615210.1
<i>P. vinckeivinckeii</i> hypothetical protein mRNA	0.016	XM_008626467.1
<i>P. chabaudichabaudi</i> DLC type 2, partial mRNA	0.016	XM_732090.1
<i>P. yoeliiyoelii</i> str. 17XNL partial mRNA	0.057	XM_721401.1
<i>P. berghei</i> strain ANKA DLC type 2 mRNA	0.057	XM_673772.1
<i>S. lycopersicum</i> chromosome, complete genome	0.69	HG975521.1
<i>G. max</i> ubiquitin-protein ligase LIN-like mRNA	0.69	XM_006586756.1

**(C). *Plasmodium cynomolgi***

<b>Description</b>	<b>E value</b>	<b>Accession</b>
<i>P. knowlesi</i> strain H DLC 2 complete cds	3e <sup>-146</sup>	XM_002259103.1
<i>P. knowlesi</i> strain H chromosome 9, complete	3e <sup>-146</sup>	AM910991.1
<i>P. cynomolgi</i> strain B DLC type 2 complete cds	5e <sup>-99</sup>	XM_004222316.1
<i>P. vivax</i> SaI-1 DLC type 2 partial mRNA	1e <sup>-86</sup>	XM_001615210.1
<i>P. inui</i> San Antonio 1 hypothetical protein mRNA	1e <sup>-67</sup>	XM_008819688.1
<i>T. versicolor</i> FP-101664 hypothetical protein mRNA	0.82	XM_008043674.1
<i>G. max</i> E3 ubiquitin-protein ligase LIN-like mRNA	0.82	XM_006586756.1

Table1: Nucleotide BLAST query results for respective *Plasmodium* species. The low E-values observed in target species implies that the hits are significant. BLASTn default algorithm parameters (expectation thresh hold of 10).

**Sequences producing significant alignments:****(A). 6PB\_TcP fwd mp20B**

Description	E value	Accession
<i>P. knowlesi</i> DLC type 2 mRNA, complete cds	3e <sup>-77</sup>	XM_002259103.1
<i>P. knowlesi</i> chromosome 9, complete genome	3e <sup>-77</sup>	AM910991.1
<i>P. vivax</i> SaI-1 DLC type 2 partial mRNA	1e <sup>-55</sup>	XM_001615210.1
<i>P. cynomolgi</i> DLC type 2 mRNA, complete cds	7e <sup>-53</sup>	XM_004222316.1
<i>P. inui</i> hypothetical protein partial mRNA	4e <sup>-43</sup>	XM_008819688.1
Feline coronavirus UU16, complete genome	2e <sup>-15</sup>	FJ938058.1
Feline coronavirus RM, complete genome	7e <sup>-09</sup>	FJ938051.1

**(B). 7PB\_TcP fwd MB5b**

Description	E value	Accession
<i>P. knowlesi</i> DLC type 2 mRNA, complete cds	1e <sup>-124</sup>	XM_002259103.1
<i>P. knowlesi</i> strain H chromosome 9, complete genome	1e <sup>-124</sup>	AM910991.1
<i>P. cynomolgi</i> DLC type 2 mRNA, complete cds	4e <sup>-80</sup>	XM_004222316.1
<i>P. vivax</i> SaI-1 DLC type 2 partial mRNA	4e <sup>-74</sup>	XM_001615210.1
<i>P. inui</i> hypothetical protein partial mRNA	4e <sup>-61</sup>	XM_008819688.1
<i>P. falciparum</i> 3D7 chromosome 11, complete sequence	5e <sup>-09</sup>	AE014186.2
<i>P. falciparum</i> 3D7 DLC 2, putative mRNA, complete cds	5e <sup>-09</sup>	XM_001347783.1
<i>P. vinckei vinckei</i> hypothetical protein partial mRNA	3e <sup>-06</sup>	XM_008626467.1
<i>P. chabaudi chabaudi</i> DLC type 2, partial mRNA	3e <sup>-06</sup>	XM_732090.1
<i>P. yoelii</i> genome assembly chromosome 9	1e <sup>-05</sup>	LM993663.1

Table2: Nucleotide BLAST query results for representative Malaria positive clinical samples

**Supplementary data:****Primer design reference nucleotide sequences:**

gi124803800reflXM\_001347783.11 *P. falciparum* 3D7 dynein light chain type 2  
 gi168073898reflXM\_673772.11 *P. berghei* strain ANKA dynein light chain type 2  
 gi170930600reflXM\_732090.11 *P. chabaudi chabaudi* dynein light chain type 2  
 gi1221056001reflXM\_002259103.11 *P. knowlesi* strain H dynein light chain type 2  
 gi1457870887reflXM\_004222316.11 *P. cynomolgi* strain B dynein light chain type 2  
 gi1156098455reflXM\_001615210.11 *P. vivax* SaI-1 dynein light chain type 2  
 gi182596995reflXM\_721401.11 *P. yoelii yoelii* str. 17XNL hypothetical protein  
 gi1457869749reflXM\_004221748.11 *P. cynomolgi* cytoplasmic dynein light chain  
 gi1156097557reflXM\_001614762.11 *P. vivax* SaI-1 cytoplasmic dynein light chain  
 gi1221054821reflXM\_002258514.11 *P. knowlesi* strain H dynein light chain mRNA  
 gi134190546lgbIBC021177.21 *Homo sapiens* Tctex1 domain containing 2, mRNA  
 gi1325974481reflNM\_152773.41 *Homo sapiens* Tctex1 domain containing 2 mRNA  
 gi1109731348lgbIBC113639.11 *Homo sapiens* t-complex-associated-testis-expressed 3, mRNA  
 gi128372534reflNM\_174910.11 *Homo sapiens* t-complex-associated-testis-expressed 3 mRNA  
 gi188758585reflNM\_198104.21 *Mus musculus* t-complex-associated testis expressed 3 mRNA  
 gi1410041476reflXM\_001138699.21 *Pan troglodytes* t-complex-associated-testis-expressed

Supplementary data: Table1. Primer design: *Plasmodium* genus, *Homo sapiens* and other reference nucleotide sequences for Tctex light chain dynein.

#### 4.0. Discussion:

This study presents new target gene for detection of *Plasmodium spp* in human peripheral blood by parasite DNA amplification in polymerase chain reaction (PCR). In effort to address the need develop alternative target genes in detection of multiple species malaria infections, different laboratories have applied various PCR methods on 18S rRNA, cytochrome b oxidase, circumsporozoite protein, tubulin and other genes [9, 30-32]. Our previous *in-silico* studies [26] had shown that *Plasmodium dlc-Tc-tex* gene is a good target in diagnostic or drug development because the gene is conserved within the genus. The results presented in this study show that PCR targeting *Plasmodium* dynein light chain *Tctex* sub-unit can be applied to differentiate *P. falciparum* in a multiple malaria infection while application of the *Plasmodium* genus specific primers can discriminate between the species tested in this study: *P. vivax*, *P. knowlesi* and *P. cynomolgi*. When tested on microscope confirmed malaria blood samples, *P. falciparum* specific primers detected 11 positives out of the 30 samples and the target PCR band intensity was presumably, reflective of parasitaemia (Fig 1a). The variation between microscopy observations and PCR results indicates other variant *Plasmodium* species are considered presumptive *P. falciparum* cases in routine clinical procedures.

Microscopic observation does not reliably distinguish between *P. falciparum*, *P. vivax*, *P. knowlesi* and *P. cynomolgi* where all these species are in transmission and is particularly important for zoonotic cases [33, 34]. PCR done on *in-vitro* *P. falciparum* cultures (3D7/Dd2) and *P. vivax*, *P. knowlesi* and *P. cynomolgi in-vivo* controls showed that the species can be differentiated by PCR target gene band sizes, approximately 300bps and 400bps (Fig 2a). When genus specific primers were applied on clinical malaria samples, both *P. falciparum* and non *P. falciparum* malaria targets and other undetermined products (Fig 2(A), (B), (C)). The genus

primers could further be optimized to produce specific target as seen in Fig 2(C). Detection of *Plasmodium* infection in clinical malaria samples using genus primers amplified the approximately 300bps target PCR product (Fig 3 (A), (B), (C)) and also a product approximately 1000bps coinciding with *P. vivax* controls (Fig 3 (A), lane 3; Fig 3 (B), lane 4; Fig 3 (C), lane 3). Some samples while positive for the 300bps PCR product were negative or had faint 1000bps product, indicating that the latter product reflect common *P. vivax* co-infection.

To determine the identity of the amplified PCR products malaria positive and control samples (Figs 3 (A), (B), (C) and 4 (A), (B)), some of the PCR products (Approx. 300bps- to 400bps, and 1000bps see Mol wt maker Fig 4 (A) and arrows Fig 4(B), (C)) were gene cleaned for sequencing purposes. These target bands could be indicative of *P. falciparum* and non-*P. falciparum* malaria, respectively and also the 1000bps product that presumably corresponded to *P. vivax* infection. The data indicate presence of *P. falciparum* and mixed infections in Kenya's malaria endemic areas and has implications on policy choice drug regimes in treatment of malaria. Presumptive *P. falciparum* cases are routinely treated with Artemisinin- Lumefantrine or other combined therapy (ACT) while other species may be treated with Primaquine or Chloroquine [22, 35]. Diagnosis of *P. vivax* and *P. cynomolgi* is required to administer anti-hyponozoite treatment to prevent relapses, while in *P. knowlesi* cases, urgency is required due to this species short replication period (12hrs) that may lead to fatalities [36, 37]. Some malaria endemic regions, for example; Papua New Guinea and Indonesia, have already adopted a unified treatment by ACT for all malaria cases [19, 38].

Prompt accurate diagnosis is precedence in the choice treatment of the different malaria cases. Currently available methods for the diagnosis of malaria in peripheral blood are parasite

detection by microscopy, DNA or RNA detection methods by polymerase chain reaction (PCR), and detection of parasite antigens by rapid diagnostic tests (RDTs). The latter test is preferred because of its ease of use, relatively low cost and also detects circulating antigens even when the parasites are sequestered in the deep circulation [39-41]. There are concerns about RDTs test stability, accuracy, species detection, due to antigen genetic diversity, justifying the need for improving current RDT and further development of promising prototypes [12]. Moreover, new RDTs will presumably be pre-tested at PCR stage. The *dlc-Tctex* PCR target used in this study showed that the gene is unique to *Plasmodium spp* [26]. BLAST results of the PCR derived sequence query indicate that *P. falciparum* gene sequence is markedly different from other *Plasmodium* species: e-value  $1e^{-151}$  compared to nearest neighbor e-value  $1e^{-53}$  in *P. berghi* (Table 1, (A)) and no significant similarity to any human gene sequence. This observation is supported by the PCR results, where *P. falciparum* primers had non-ambiguous single band target amplifications (Figure 1a, Figure 1b). BLAST e-values for sequence query from PCR primers targeting non-*P. falciparum* malaria indicate that *Plasmodium* species cluster differences; where, *P. knowlesi* and *P. cynomolgi* are in the same sub-group (Table 1, (B) & (C)) and *P. vivax dlc-Tctex* sequence is very closely related. The expectation values scores were interchangeably similar (e-value  $1e^{-158}$  and  $1e^{-146}$ ) and distinct to the subgroup. This demonstrates the difficulty in designing genus specific PCR primers for this sub-group. Malaria clinical samples amplified using primers targeting non-*P. falciparum* infection had similar sequence high score results within the sub-group, where *P. knowlesi*, *P. cynomolgi* and *P. vivax* cluster had relatively similar e-values (Table 2, (A) & (B)) indicating these primers can be applied to detect this subclass of *Plasmodium* species based on different molecular size products (Fig 3 (A), (B), (C)). While the different species showed variation in molecular weight of the PCR band, the clinical malaria

samples did not have high yield distinct bands and the sequencing results were not of particularly high quality. It is necessary to do further re-sequencing of optimized PCR products of targeted non-*P. falciparum* in mixed malaria infections to achieve better results.

Transmission of mixed species infections in endemic regions is related to transmitting mosquito vectors and the proximity of the alternate host. In tropical and subtropical forested Southeast Asia, the importance of zoonoses malaria transmission by non-human primates is increasingly being reported [8, 10, 13]. Such occurrence is expected in areas in sub-Saharan Africa, especially due to the close proximities between human and wild animals as people are encroaching forested areas for farming and urbanization. *P. knowlesi* had been considered simian malaria until recently when PCR diagnosis [10, 13, 23] showed it is misdiagnosed for *P. falciparum* at ring stage and as *P. malariae* in other stages. Similarly, *P. cynomolgi* is indistinguishable from *P. vivax* and discriminative PCR is necessary to separate the two. The reality of mixed malaria infections requires effective diagnostic tools so that the right treatment strategies are followed and the government can then recommend a more rational drug treatment policy [21-22]. *P. knowlesi* has the shortest life cycle known for *Plasmodium* and this can lead to high parasitaemia and possible fatality [14] while *P. cynomolgi* presents hyponozoites which can initiate relapses just as the case in *P. vivax* [8]. The Target gene (*dlc-Tctex*) sequence BLAST results from clinical samples in this study indicate that *P. falciparum* and *P. vivax* mixed infection are likely, very common while *P.knowlesi/P.cynomolgi zoonotic* infections are probable in Kenyan human population in malaria endemic areas. Further refinement of this data will give clear evidence of the zoonoses transmission of primate malaria in this region.

## 5.0. Conclusions:

PCR targeting *Plasmodium dlc-Tctex* gene can specifically detect *P. falciparum* and differentiate the species in mixed infection.

Various *Plasmodium* species have distinctive molecular size PCR band.

*dlc-Tctex* sequences BLASTn e-Value scores show distinctive clusters within *Plasmodium spp* and are markedly different compared to human orthologues.

**References:**

1. C. Luxemburger, F. Nosten, N. White, Naturally acquired immunity to *vivax* malaria. *Lancet*. 10, (1999) 162.
2. J. Sachs, P. Malaney, The economic and social burden of malaria. *Nature* 7, 415 (2002) 680-5.
3. F. Nosten, M. Van Vugt, R. Price, C. Luxemburger, K. Thway et al, Effects of artesunate-mefloquine combination on incidence of *Plasmodium falciparum* malaria and mefloquine resistance in western Thailand: a prospective study. *Lancet*, 356 (2000) 297–302.
4. T. Hartman, S. Rogerson, P. Fischer, The impact of maternal malaria on newborns. *Ann Trop Paediatr*. 30 (2010) 271-82.
5. C. Cunha, B. Cunha, Brief history of the clinical diagnosis of malaria: from Hippocrates to Osler. *J Vector Borne Dis*. 45 (2008) 194-9.
6. S. Kappe, A. Vaughan, J. Boddey, A. Cowman, That was then but this is now: malaria research in the time of an eradication agenda. *Science*, 14;328 (2010) 862-6.
7. G. Lee, E. Jeon, D. Le, T. Kim, J. Yoo et al., Development and evaluation of a rapid diagnostic test for *Plasmodium falciparum*, *P. vivax*, and mixed-species malaria antigens. *Am J Trop Med Hyg*. 85. (2011) 989-93.
8. T. Ta, S. Hisam, M. Lanza, A. Jiram, N. Ismail et al., First case of a naturally acquired human infection with *Plasmodium cynomolgi*. *Malar J.*, 24 (2014) 13:68.

9. W. Collins, J. Sullivan, G. Jeffery, D. Nace, T. Williams et al., Mosquito infection studies with Aotus monkeys and humans infected with the Chesson strain of *Plasmodium vivax*. *Am J Trop Med Hyg.* 86 (2012) 398-402.
10. N. Khim, S. Siv, S. Kim, T. Mueller, E. Fleischmann, et al., *Plasmodium knowlesi* infection in humans, Cambodia, 2007-2010. *Emerg Infect Dis.* 17 (2011) 1900-2.
11. N. Singh, O. Kataria, M. Singh, The changing dynamics of *Plasmodium vivax* and *P. falciparum* in central India: trends over a 27-year period (1975--2002). *Vector Borne Zoonotic Dis.* 4 (2004) 239-48.
12. W. Chin, P. Contacos, W. Collins, M. Jeter, E. Alpert, Experimental mosquito-transmission of *Plasmodium knowlesi* to man and monkey. *Am J Trop Med Hyg.* 17 (1968) 355-8.
13. J. Cox-Singh, B. Singh, *Knowlesi* malaria: newly emergent and of public health importance? *Trends Parasitol.* 24 (2008) 406-10.
14. J. Cox-Singh, J. Hiu, S. Lucas, P. Divis, M. Zulkarnaen, Severe malaria - a case of fatal *Plasmodium knowlesi* infection with post-mortem findings: a case report. *Malar J.* 11 (2010) 9-10.
15. M. Marks, A. Gupta-Wright, F. Doherty, M. Singer, D. Walker, Managing malaria in the intensive care unit. *Br J Anaesth.* 113 (2014) 910-921.
16. S. Mishra, P. Panigrahi, R. Mishra, S. Mohanty, Prediction of outcome in adults with severe *falciparum* malaria: a new scoring system. *Malar J;* 6 (2007) 24
17. M. English, Life-threatening severe malarial anaemia. *Trans R Soc Trop Med Hyg.* 94 (2000) 585-8.

18. F. Bruneel, F. Tubach, P. Corne, B. Megarbane, J. Mira, et al., Severe Imported Malaria in Adults (SIMA) Study Group. Severe imported falciparum malaria: a cohort study in 400 critically ill adults. *PLoS One*. 5 (2010) e13236.
19. K. Marsh, D. Forster, C. Waruiru, I. Mwangi, M. Winstanley, et al., Indicators of life-threatening malaria in African children. *N Engl J Med*. 25; 332 (1995) 1399-404.
20. World Health Organization, *Guidelines for the Treatment of Malaria*. Geneva: World Health Organization; (2010) 1–194.
21. E. Ruizendaal, S. Dierickx, K. Grietens, H. Schallig, F. Pagnoni, et al., Success or failure of critical steps in community case management of malaria with rapid diagnostic tests: a systematic review. *Malar J*, 13 (2014 ) 229
22. B. Dinko, M. Oguike, J. Larbi, T. Bousema, C. Sutherland, Persistent detection of *Plasmodium falciparum*, *P. malariae*, *P. ovale curtisi* and *P. ovale wallikeri* after ACT treatment of asymptomatic Ghanaian school-children. *Int J Parasitol Drugs Drug Resist*. 3 (2013). 45-50.
23. C. Chew, Y. Lim, P. Lee, R. Mahmud, K. Chua, Hexaplex PCR detection system for identification of five human *Plasmodium* species with an internal control. *J Clin Microbiol*. 50 (2012) 4012-9.
24. N. Lucchi, A. Demas, J. Narayanan, D. Sumari, A. Kabanywany, S. Kachur, J. Barnwell, V. Udhayakumar, Real-time fluorescence loop mediated isothermal amplification for the diagnosis of malaria. *PLoS One*. 29;5 (2010) e13733.
25. T. Mixson-Hayden, N. Lucchi, V. Udhayakumar, Evaluation of three PCR-based diagnostic assays for detecting mixed *Plasmodium* infection. *BMC Res Notes*. 31 (2010) 3:88.

26. E. Githui, E. De Villiers, A. McArthur, *Plasmodium* possesses dynein light chain classes that are unique and conserved across species. *Infect Genet Evol.* 9 (2009) 337-43.
27. A. Tai, Z. Chuang, C. Bode, U. Wolfrum, C. Sung, Rhodopsin's carboxyterminal cytoplasmic tail act as a membrane receptor for cytoplasmic dynein by binding to the dynein light chain Tctex-1. *Cell* 97 (1999) 877-87.
28. Altschul SF, Madden TL, Schäffer AA, Zhang J, Zhang Z. et al. (1997). Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. *Nucleic Acids Res.* 25(17):3389-402.
29. A. Schäffer, L. Aravind, T. Madden, S. Shavirin, J. Spouge et al., Improving the accuracy of PSI-BLAST protein database searches with composition-based statistics and other refinements. *Nucleic Acids Res.* 29 (2001) 2994-3005.
30. malERA Consultative Group on Diagnoses and Diagnostics, A research agenda for malaria eradication: diagnoses and diagnostics. *PLoS Med.* 8 (2011). e1000396.
31. B. Barber, T. William, M. Grigg, K. Piera, T. Yeo, N. Anstey, Evaluation of the sensitivity of a pLDH-based and an aldolase-based rapid diagnostic test for diagnosis of uncomplicated and severe malaria caused by PCR-confirmed *Plasmodium knowlesi*, *Plasmodium falciparum* and *Plasmodium vivax*. *J Clin. Microbiol.* 51 (2013) 1118-23
32. N. Lucchi, M. Poorak, J. Oberstaller, J. DeBarry, G. Srinivasamoorthy et al, A new single-step PCR assay for the detection of the zoonotic malaria parasite *Plasmodium knowlesi*. *PLoS One.* 7(2) (2012) e31848.

33. J. Cox-Singh, T. Davis, K. Lee, S. Shamsul, A. Matusop, et al., *Plasmodium knowlesi* malaria in humans is widely distributed and potentially life threatening. Clin Infect Dis.46 (2008) 165-71.
34. B. Barber, T. William, M. Grigg, T. Yeo, N. Anstey, Limitations of microscopy to differentiate *Plasmodium* species in a region co-endemic for *Plasmodium falciparum*, *Plasmodium vivax* and *Plasmodium knowlesi*. Malar J. 8 (2013) 12: 8. doi: 10.1186/1475-2875-12-8.
35. B. Barber, T. William, M. Grigg, J. Menon, S. Auburn et al., A prospective comparative study of *knowlesi*, *falciparum*, and *vivax* malaria in Sabah, Malaysia: high proportion with severe disease from *Plasmodium knowlesi* and *Plasmodium vivax* but no mortality with early referral and artesunate therapy. Clin Infect Dis.56 (2013). 383-97
36. T. William, J. Menon, G. Rajahram, L. Chan, G. Ma et al., Severe *Plasmodium knowlesi* malaria in a tertiary care hospital, Sabah, Malaysia. Emerg Infect Dis. 17 (2011) 1248-55.
37. T. William, H. Rahman, J. Jelip, M. Ibrahim, J. Menon. et al Increasing incidence of *Plasmodium knowlesi* malaria following control of *P. falciparum* and *P. vivax* Malaria in Sabah, Malaysia. PLoSNeglTrop Dis. 7 (2013). e2026.
38. G. Mombo-Ngoma, C. Kleine, A. Basra, H. Würbel, D. Diop. et al., Prospective evaluation of artemether-lumefantrine for the treatment of non-*falciparum* and mixed-species malaria in Gabon. Malar J. 11: (2012) 120. doi: 10.1186/1475-2875-11-120.
39. D. Mason, F. Kawamoto, K. Lin, A. Laoboonchai, C. Wongsrichanalai, A comparison of two rapid field immunochromatographic tests to expert microscopy in the diagnosis of malaria. Acta Trop. 82 (2002) 51-9.

40. T. Davis, I. Mueller, S. Rogerson. Prevention and treatment of malaria in pregnancy. *Future Microbiol.* 5 (2010). 1599-613.

41. P. Gillet, P. Mukadi, K. Vernelen, M. Van Esbroeck, J. Muyembe et al, External quality assessment on the use of malaria rapid diagnostic tests in a non-endemic setting. *Malar J.* 9 (2010) 359. doi: 10.1186/1475-2875-9-359.